<SEC-DOCUMENT>0001387131-16-005927.txt : 20160629
<SEC-HEADER>0001387131-16-005927.hdr.sgml : 20160629
<ACCEPTANCE-DATETIME>20160629170017
ACCESSION NUMBER:		0001387131-16-005927
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160629
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160629
DATE AS OF CHANGE:		20160629

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		161739505

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_062916.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">Washington,
D.C. 20549</FONT></P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-transform: uppercase; text-align: center">SECURITIES
EXCHANGE ACT OF 1934
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event
reported): June 29, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>TherapeuticsMD, Inc.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">(Exact Name of Registrant as Specified
in its Charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-00100</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>87-0233535</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or Other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Jurisdiction of Incorporation)</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">6800 Broken Sound Parkway NW,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Third Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Boca Raton, FL 33487</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding: 0; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Office) (Zip Code)</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Registrant's telephone number, including area code: (561) 961-1900</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<I>see</I> General Instruction A.2 below):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-bottom: 12pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; font-size: 10pt; padding: 0"><B>Item 7.01</B></TD>
    <TD STYLE="padding: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Regulation FD Disclosure.</B></P></TD>
    <TD STYLE="width: 0%; font-size: 10pt; padding: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 13.2pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">TherapeuticsMD,
Inc. is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a press release issued on June 29, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The information in this Current Report on Form
8-K (including the exhibit) is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be &ldquo;filed&rdquo;
for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that
section, nor will any of such information or exhibits be deemed incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference
in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 44pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><B>Item&nbsp;9.01.</B></TD>
    <TD COLSPAN="3" STYLE="text-align: justify"><B>Financial Statements and Exhibits.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom">(d)&#9;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify"><I>Exhibits.</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 1in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Exhibit</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Number</U></P></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-decoration: underline"><U>Description</U></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">99.1</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Press Release from TherapeuticsMD, Inc. dated June 29, 2016, entitled
        &quot;TherapeuticsMD Announces Filing Timeline for Yuvvexy (TX-004HR) New Drug Application.&rdquo;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 13.2pt; text-align: justify; text-indent: 27.5pt">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top">Date: June 29, 2016</TD>
    <TD COLSPAN="2">THERAPEUTICSMD, INC.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 60%">&nbsp;</TD>
    <TD STYLE="width: 7%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 33%">/s/<I> Daniel A. Cartwright</I></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title:</P></TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Daniel A. Cartwright</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6.6pt; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 1in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Exhibit</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Number</U>&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom; text-decoration: underline"><U>Description</U></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify">99.1</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A HREF="ex99-1.htm">Press Release from TherapeuticsMD, Inc. dated June 29, 2016, entitled &quot;TherapeuticsMD Announces Filing Timeline for Yuvvexy (TX-004HR) New Drug Application.&rdquo;</A></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><A HREF="txmd-8k_062916.htm">TherapeuticsMD, Inc. 8-K</A></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 100%; text-align: right; vertical-align: bottom; padding: 0"><IMG SRC="txmd_logo.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">FOR IMMEDIATE RELEASE</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TherapeuticsMD Announces Filing Timeline
for Yuvvexy (TX-004HR) New Drug Application</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><B>BOCA RATON, Fla., June 29,
2016</B> &ndash; TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women&rsquo;s healthcare company, announced today that it
expects that the New Drug Application (NDA) for Yuvvexy, the conditionally approved trade name for the Company&rsquo;s TX-004HR
drug candidate, will be submitted to the Food and Drug Administration (FDA) on or before July 15, 2016. The NDA is being finalized
in Electronic Common Technical Document (eCTD) format and will be submitted to the FDA following electronic publishing activities
and technical document validation.&nbsp; Yuvexxy is an applicator-free, vaginal, estradiol softgel capsule being proposed for the
treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA)
due to menopause. TherapeuticsMD completed the phase 3 Rejoice Trial for Yuvvexy in December 2015.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About TherapeuticsMD, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">TherapeuticsMD, Inc.&nbsp;is an innovative
healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA&trade; technology,&nbsp;TherapeuticsMD&nbsp;is
developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage
forms and administration routes. The company&rsquo;s clinical development pipeline includes two phase 3 products. The company also
manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins under the
vitaMedMD<SUP>&reg;</SUP> and BocaGreenMD<SUP>&reg;</SUP> brands.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release by TherapeuticsMD,
Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating
to TherapeuticsMD&rsquo;s objectives, plans and strategies as well as statements, other than historical facts, that address activities,
events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These
statements are often characterized by terminology such as &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;should,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;will,&rdquo; &ldquo;expects,&rdquo; &ldquo;estimates,&rdquo;
&ldquo;projects,&rdquo; &ldquo;positioned,&rdquo; &ldquo;strategy&rdquo; and similar expressions and are based on assumptions and
assessments made in light of management&rsquo;s experience and perception of historical trends, current conditions, expected future
developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the
date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of
new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject
to risks and uncertainties, many of which are outside of the company&rsquo;s control. Important factors that could cause actual
results, developments and business decisions to differ materially from forward-looking statements are described in the sections
titled &ldquo;Risk Factors&rdquo; in the company&rsquo;s filings with the Securities and Exchange Commission, including its most
recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following:
the company&rsquo;s ability to maintain or increase sales of its products; the company&rsquo;s ability to develop and commercialize
its hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and uncertain results
of the company&rsquo;s clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval
of the company&rsquo;s hormone therapy drug candidates; the company&rsquo;s reliance on third parties to conduct its clinical trials,
research and development and manufacturing; the availability of reimbursement from government authorities and health insurance
companies for the company&rsquo;s products; the impact of product liability lawsuits; the influence of extensive and costly government
regulation; the volatility of the trading price of the company&rsquo;s common stock and the concentration of power in its stock
ownership. PDF copies of the company&rsquo;s historical press releases and financial tables can be viewed and downloaded at its
website: www.therapeuticsmd.com/pressreleases.aspx.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"># # #</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Contact:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Investors</U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">David Delucia</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Director of Investor Relations</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">561-961-1900</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">David.Delucia@TherapeuticsMD.com</P>



<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>txmd_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  E /4# 2(  A$! Q$!_\0
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M;WXB7'A&+7](D\46EN+N?25ND-Y%"=I$ABSN"_,O./XA705^8?[7/@[QH?\
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MSVTES'<-';JNI?9\O&S+Q$4  / 4"OIGQ!\'O^"B_P =/#G_  @_B'QK\'_
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M_6TDVUKJK*Y\^_\ !'.PM?BE_P %1/VPO&OBR*.;X@Z+XD_L>Q%P0\NG:?\
M:+J(K&?[NRWMTR.BH!GYJ_2#QE\,_#OQ$N=(FU[0]*UF7P_?)J6F/>VJ3M87
M2@A9HBP.QP&.&'(S7Q7^V?\ \$P?B):?M2R_M _LS^,=,\$_$S4+;[-X@TK5
M%)TOQ(@"C+?*P5R$0,"N"45@R,"QQ/"W[*/[:?[4GQ?\+ZC\:/BAX8^&O@SP
MEJ,.I_V5\/W=+K5YH\$!W<'Y#@@AW=>3^[/!'/BHTL3)8F-517*E9WNK*UDN
MOE^)UX.5;"0>$G1E)\S=U:TDW>[;>C76_;0F_;P_8+^.?A/]N2V_:7_9RU#P
MYJ7BV;1UT76_#>NE4BOX455'E.Q5<,$CR"\;!HP0YW%1T7[%7_!676/BI^TM
M;?!GXX?"O4/A#\7+JSDFTM9&\ZQUB-5+N(7(RN1&S##.C>41OW  WOVJ_P!F
MS]K7PQ^T=J_Q'^!?Q;T#5-'UJ.".X\#>+[<C3[01*$_T=D4XW<LQ!B8ECEFX
MQSO[,?[ ?QQ^*_[;N@_'[]I;7?!1UGP/I\VG^&/#GA>)_LMH9!(K32.XSTED
M(&YR25Y4+M.G-1GAO]HE%VC[K5U-/I&W5=/3J9\E>GB_]EC./-*\D[.#5]9)
M[IVULNO0]#^#HS_P6"^+W_8GZ=_*WKS/XM_\$Z_'4?[0=]X \':A<:5\!/B?
M?)X@\1PV^%&ER0,&FMHS_ )B8]H'' !&(N?H_P !?LUZYX6_;R\=_%">YTQM
M!\3Z#::7:P)(YNDDB\K<74J%"_(<88GIQ7N-82S.5&HI46G[D5\TEKZQ>QY%
M#A.EC\-4I8^+BU7JR5G9N$INZO\ R5(NTEU7FD?&G_!1GPS8>"_&O[+ND:5:
M0V.FZ9X_T^UM;>%=J01(T2JH'H !5SXMPN?^"S_PK?:VP>";P%L< YO>]=I_
MP4"_9B\;_M#/\.=1\!W?AJUUGP'X@374_MMY5MY&CVE 1&C$C<HR...]89L?
MVR2^[[1^SWN'&?*U/-;T*L7AX>_&_+.+N[?$WKLSSLQP=6&95TZ-3D]I0J1<
M(<R:I1C>.ZMJK>78^IR<"OBS]A"XB^+G_!0_]H?XBZ-*UQX8:2TT&VN5.8;R
M>*.-9"AZ,!Y&01_#*I[UI^*/V:_VGOVB()=%\=_$_P &>#?"UW\E[#X-LYC=
M7<1&&C$DRAD![X<CDY!'%?1WP$^ WAK]FKX8:?X1\)V/V'2=/!(W'=+<2'[\
MLC?Q.QZGZ    #CO2PM"<5-2G-6TV2NF]>^G0]QK%YOC\/6G0E2HT).=YV4I
MSY91244W:*4FVW9MV26[.RHHHKR3[4**** "BBB@ HHHH **** "BBB@ KS7
M]GW]D/X=_LL:CXLN_ ?A[^PKCQSJ;:QK;_;[FZ^VW;%B9,32.$Y=OE3:O/2B
MBJ4Y*+BGH]_,B5.$I*<EJMGV]#TJBBBI+"BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
